Saudi Arabia-based Ajlan & Bros Medical Company has signed a Memorandum of Understanding (MoU) with the genomics and biopharmaceutical specialist, Malaysian Genomics Resource Centre Berhad, to explore the distribution of biopharmaceutical and genetic screening services in the Middle East and North Africa (MENA) region.
Ajlan is part of a multinational conglomerate Ajlan & Bros established in 1979 with extensive global private equity, real estate, and industrial investments.
As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cells, and exosome products.
Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the MENA region for areas such as agriculture, aquaculture, plantations, healthcare, and industrial biotechnology.
Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group, said that, “We look forward to working with Malaysian Genomics to bring its biopharmaceutical and genetic services and products to Saudi Arabia, which is a good launchpad to the Middle East and North Africa region. This MoU is just the beginning as we explore how we can work closely together in the coming months.”
Malaysian Genomics on its part will analyze samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.
“This is a really good opportunity for us to explore the MENA market for our products and services, especially in the area of R&D where we see a lot of growth, especially in agriculture and aquaculture due to climate change impact and the health diagnosis for distinct population groups,” commented Mr. Noor Azri Noor Azerai, Executive Director of Malaysian Genomics.
